Retrospective cohort study assesses adverse events and healthcare resource utilization of CAR T in DLBCL and MCL, suggesting critical management considerations.
Key Points
A high prevalence of cytokine release syndrome was observed in CAR T patients, with significant variability across diseases.
Among patients treated with CAR T, admission to the ICU occurred in about 14% of mantle cell lymphoma cases, highlighting acute care needs.
The analysis utilized a retrospective cohort design based on EHR-derived data from diverse oncology practices across the US.
The findings support the feasibility of managing CAR T therapy safely across various community settings, emphasizing the urgent need for effective adverse event strategies.